Detalhe da pesquisa
1.
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
N Engl J Med
; 378(18): 1671-1680, 2018 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29668352
2.
Mapping the COPD Assessment Test onto EQ-5D.
Value Health
; 19(4): 469-77, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27325339
3.
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
COPD
; 13(1): 1-10, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26451734
4.
A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.
Health Qual Life Outcomes
; 13: 177, 2015 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-26520062
5.
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
Respir Res
; 15: 78, 2014 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25015176
6.
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
BMC Pulm Med
; 14: 2, 2014 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-24393134
7.
Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease.
Health Qual Life Outcomes
; 11: 196, 2013 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-24229361
8.
28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.
Pulm Pharmacol Ther
; 25(6): 465-71, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22955035
9.
Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
Respir Med
; 114: 123-6, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27109822
10.
Is Blood Eosinophil Count a Predictor of Response to Bronchodilators in Chronic Obstructive Pulmonary Disease? Results from Post Hoc Subgroup Analyses.
Clin Drug Investig
; 35(10): 685-8, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26329916
11.
Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients.
Respir Physiol Neurobiol
; 185(2): 393-9, 2013 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23026438
12.
Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease.
BMJ Open
; 3(10): e003048, 2013 Oct 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-24154513
13.
A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
Respir Med
; 106(7): 970-9, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22498110
14.
Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Int J Chron Obstruct Pulmon Dis
; 7: 153-64, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22419863
15.
Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
Clin Respir J
; 6(4): 248-57, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22329914